Difference between revisions of "WG6 Nonclinical - Historical Controls"

From PHUSE Wiki
Jump to: navigation, search
(Conference Calls and Minutes)
Line 116: Line 116:
[[Category:FDA Working Groups]]
[[Category:FDA Working Groups]]
<!-- Use one of the following Categories based on your WG: Data Validation ; Site Selection ; Data Integration ; Data Conversion ; CDISC Implementation; Standard Scripts ; Non-Clinical >
<!-- Use one of the following Categories based on your WG: Data Validation ; Site Selection ; Data Integration ; Data Conversion ; CDISC Implementation; Standard Scripts ; Non-Clinical >

Revision as of 15:21, 30 May 2013

Call for Participation

The Nonclinical Historical Control (HC) Project is seeking interested participants from industry, academia, and governmental organizations to identify the most promising projects related to historical control data at various levels of aggregation. With the rise of electronic nonclinical datasets, is it time to consider how we might more effectively harness decades of untreated control data? If your organization is interested in the following kinds of questions, you may be interested in our group:

  • Is there utility in agreeing upon a format for such data for easier sharing?
  • How can historical control data be harnessed to speed drug development?
  • Is it possible to aggregate data at various levels and retain validity?
  • Can historical controls supplement or supplant concurrent controls?

Join colleagues from the FDA in identifying and prioritizing potential projects and be a part of the next generation of stakeholder consultation at FDA.

Who We Are

The Nonclinical Historical Control (HC) Project is part of the of the FDA/PhUSE Computational Sciences Nonclinical Working Group. Learn more about the larger working group at Non-Clinical Road-map and Impacts on Implementation.


During a broad survey of needs and challenges related to nonclinical data, issues related to historical control data were a top concern of stakeholders across organizations. There is a perception that there may be additional ways to make further use of historical control data to enhance studies or submissions across industry, academia, and government.

During the working sessions of the FDA/PhUSE Computational Sciences Symposium, participants discussed options for identifying the highest priority projects in this area. There was agreement that the idea of "historical control data" had several connotations which should be clarified prior to proceeding with this project.


Develop recommendations for high priority projects regarding the use of historical control data. These recommendations could include identification of areas where additional aggregation or analaysis of historical control data may be useful or identification of data standards to develop and pilot for exchange of historical data.

Plans & Milestones

  1. Identify established definitions of historical controls (by June 2012). This should include categorizations of common types of historical control data.
  2. Gather suggestions for improvements in HC data and perceived uses/benefits of HC at different levels of aggregations (by September 2012)
  3. Identify the highest priorities of these uses based on utility, feasibility, and validity (by March 2013)



  1. Identify participants and project leads
  2. Gather published definitions of HC data or from other sources (see Working page for definitions) and relevant papers evaluating uses of HC data
  3. Drafted industry survey (final review in progress) to distributed to a broad nonclinical audience through various personal and industry contact lists
  4. Agreed to Instem electronic survey tools to publish survey, gather responses and analyze results
  5. Agreed on survey questions, and mechanisms for surveying relevant stakeholders
  6. Drafted electronic survey courtesy Instem


  1. Establish ranking mechanism for survey questions draft survey
  2. Distribute survey and collect responses
  3. Evaluate responses according to agreed upon parameters and prioritize list
  4. Draft white paper
  5. Circulate white paper to WG6 members for comments
  6. Publish in appropriate forum


March 2012 - March 2013

  • List of prioritized HC data projects and recommendations of next steps.

Participation needs

The following types of stakeholders are encouraged to participate:

  • Pharma / CRO - Scientific & Informatics Staff
  • Vendors - Animal suppliers, Software/LIMS providers
  • FDA - Pharmacologists, Toxicologists, Statisticians

Suggested maximum of 1-2 participants per organization

Contact Lauren Mihalcik or Jen Feldmann (contact info below) to learn more or sign up.


  • Teleconferences will be held as appropriate (2/month)
  • Time commitment: ~4 hours/month (Tcons and offline work)
  • Quarterly updates to overall WG.

*Contact Lauren Mihalcik [lauren.mihalcik (at) fda.hhs.gov] or Jennifer Feldman [jennifer.feldmann (at) instem.com] to participate or with any questions

Working Group Participants

Jennifer Feldmann, Instem (co-lead)

Lauren Mihalcik, FDA (co-lead)

Jennifer Feldmann, Instem

Paul Brown, FDA

Serge Rochon, Charles River Laboratories

Joyce Zandee, INDS Inc.

Judy Henck, Eli Lilly

Nancy Everds, Amgen

Conference Calls and Minutes

30Apr2012 11Jun2012 9Jul2012 23Jul2012 6Aug2012 17Sept2012 15Oct2012 26Nov2012 1Apr2013


FDA comments are an informal communication and represent the individual's best judgment. These comments do not bind or obligate FDA. The contents of this wiki are from the individual contributors and do not necessarily reflect the view and/or policies of the Food and Drug Administration, the employers of the individuals involved or any of their staff.

Last revision by DanBoisvert,05/30/2013